A comprehensive global and regional analysis of human Brucellosis incidence

Bris­tol My­ers Squibb scored a con­fir­ma­to­ry tri­al win for Kraza­ti, the KRAS in­hibitor it picked up ear­li­er this year through its $4.8 bil­lion ac­qui­si­tion of

Up­dat­ed da­ta from a tri­al of John­son & John­son’s ex­per­i­men­tal “pret­zel” showed that more than 80% of blad­der can­cer pa­tients who got the treat­ment saw